Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty – The Rotterdam Study

Komal Waqas; Jinluan Chen; T. Lu; B. C.J. van der Eerden; Fernando Rivadeneira; André G. Uitterlinden; Trudy Voortman; M. Carola Zillikens

doi:10.1016/j.bone.2022.116564

Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty – The Rotterdam Study

Komal Waqas, Jinluan Chen, T. Lu, B. C.J. van der Eerden, Fernando Rivadeneira, André G. Uitterlinden, Trudy Voortman, M. Carola Zillikens^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

162 Downloads (Pure)

Abstract

Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) – an AGE prototype – and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of ≥3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 ± 9.9 years and dCML intake 3.3 ± 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01–1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86–1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91–1.07)] or frailty [OR = 1.01 (0.83–1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.

Original language	English
Article number	116564
Journal	Bone
Volume	165
DOIs	https://doi.org/10.1016/j.bone.2022.116564
Publication status	Published - Dec 2022

Bibliographical note

Funding Information:
The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University, Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam, in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367. The Jaap Schouten Foundation, Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study.

Funding Information:
The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University , Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative , the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports , the European Commission (DG XII), and the Municipality of Rotterdam , in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367 . The Jaap Schouten Foundation , Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study.

Publisher Copyright: © 2022 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bone.2022.116564Licence: CC BY

1-s2.0-S8756328222002411-mainFinal published version, 748 KBLicence: CC BY

Cite this

@article{1f15c7d3582d48d987016f95d3fe14fc,

title = "Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty – The Rotterdam Study",

abstract = "Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) – an AGE prototype – and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of ≥3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 ± 9.9 years and dCML intake 3.3 ± 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01–1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86–1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91–1.07)] or frailty [OR = 1.01 (0.83–1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.",

author = "Komal Waqas and Jinluan Chen and T. Lu and {van der Eerden}, {B. C.J.} and Fernando Rivadeneira and Uitterlinden, {Andr{\'e} G.} and Trudy Voortman and Zillikens, {M. Carola}",

note = "Funding Information: The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University, Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam, in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367. The Jaap Schouten Foundation, Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study. Funding Information: The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University , Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative , the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports , the European Commission (DG XII), and the Municipality of Rotterdam , in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367 . The Jaap Schouten Foundation , Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = dec,

doi = "10.1016/j.bone.2022.116564",

language = "English",

volume = "165",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty – The Rotterdam Study

AU - Waqas, Komal

AU - Chen, Jinluan

AU - Lu, T.

AU - van der Eerden, B. C.J.

AU - Rivadeneira, Fernando

AU - Uitterlinden, André G.

AU - Voortman, Trudy

AU - Zillikens, M. Carola

N1 - Funding Information: The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University, Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam, in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367. The Jaap Schouten Foundation, Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study. Funding Information: The Rotterdam Study is supported by Erasmus Medical Center and Erasmus University , Netherlands Organisation for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative , the Ministry of Education, Culture and Science, Netherlands the Ministry for Health, Welfare and Sports , the European Commission (DG XII), and the Municipality of Rotterdam , in the Netherlands. FR is supported by the Netherlands Organisation for Scientific Research (NWO) and ZonMW Project number NWO/ZONMW-VIDI-016-136-367 . The Jaap Schouten Foundation , Rotterdam, The Netherlands, kindly provided funding for the analyses of Advanced Glycation End Products related to musculoskeletal health in the Rotterdam Study. The funding sources had no role in the study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the article for publication. KW, JC, TL, AGU, FR, TV and MCZ declare no conflicts of interest related to this study. Publisher Copyright: © 2022 The Authors

PY - 2022/12

Y1 - 2022/12

N2 - Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) – an AGE prototype – and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of ≥3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 ± 9.9 years and dCML intake 3.3 ± 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01–1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86–1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91–1.07)] or frailty [OR = 1.01 (0.83–1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.

AB - Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) – an AGE prototype – and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of ≥3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 ± 9.9 years and dCML intake 3.3 ± 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01–1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86–1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91–1.07)] or frailty [OR = 1.01 (0.83–1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.

UR - http://www.scopus.com/inward/record.url?scp=85139022709&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2022.116564

DO - 10.1016/j.bone.2022.116564

M3 - Article

C2 - 36150657

AN - SCOPUS:85139022709

SN - 8756-3282

VL - 165

JO - Bone

JF - Bone

M1 - 116564

ER -

Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty – The Rotterdam Study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this